沙利度胺对复发性阿弗他溃疡患者外周血淋巴细胞亚群的影响  

Observation the effect of Thalidomide treatment of recurrent aphthous ulcers on peripheral lymphocyte populations

作　　者：罗志晓[1] 艾俊[1] 陈明月[1] 冷卫东[1] 

机构地区：[1]十堰市太和医院口腔医学中心,湖北医药学院附属医院,湖北十堰442000

出　　处：《临床口腔医学杂志》2016年第11期684-686,共3页Journal of Clinical Stomatology

摘　　要：目的:观察沙利度胺对复发性阿弗他溃疡(RAU)患者外周血淋巴细胞亚群的影响及治疗疗效。方法:选择轻型RAU患者(轻型RAU组)85例,健康对照组80例,随访观察服用沙利度胺25 mg/d治疗轻型RAU的疗效;同时比较健康对照组,轻型RAU组治疗前后外周血淋巴细胞亚群检测结果。结果:和健康对照组相比,轻型RAU患者CD4+T淋巴细胞数目减少,CD8+T淋巴细胞增多,淋巴细胞亚群比例失调;经沙利度胺治疗后,轻型RAU患者淋巴细胞亚群比例异常改善,同时患者溃疡间歇期明显延长,溃疡数目明显减少,差异均具有统计学意义(P<0.05)。结论:轻型RAU患者存在外周血T淋巴细胞亚群比例异常,沙利度胺可有效调节CD4^+、CD8^+T淋巴细胞亚群比例,延长溃疡间歇期,减少溃疡发作,临床疗效满意。Objective： To observe the clinical efficacy of Thalidomide in the treatment of Recurrent Aphthous Ulcers（ RAU） and its impact on subsets of lymphocytes in the peripheral circulation. Methods： Thalidomide was administered to 85 patients with RAU minor at 25 mg per day. The clinical effect was measured by comparing the remission time and the number of ulcers pre-and post-intervention. Meanwhile,the total number of peripheral lymphocytes and the ratio of CD4＋T cell to CD8＋T cells were measured before and after the intervention compared with the control group consisted of health participants. Results： Compared to the control group,there was a significant decrease of CD4＋T cells and increase of CD8＋T cells（ P 0. 05） in the patients with RAU minor before the treatment. The ratio of the two subsets was also abnormal. After the intervention,the ratio of the lymphocyte subsets was improved. Meanwhile,there was a significant increase in the remission time of the ulcers and reduced in the number of ulcers in patient group（ P 0. 05）. Conclusion： The ratio of the peripheral lymphocyte subsets is abnormal in patients with RAU. Thalidomide has a significant effect in correcting the abnormal ratio of CD4＋T cells to CD8＋T cells. It can also increase the remission time of ulcers and reduce the frequency of ulcer breakouts.The clinical efficacy has been satisfactory.

关 键 词：复发性阿弗他溃疡 沙利度胺 淋巴细胞亚群 疗效 

分 类 号：R781.5[医药卫生—口腔医学]